Literature DB >> 12918068

Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes.

Julia S Schleypen1, Marion Von Geldern, Elisabeth H Weiss, Nicole Kotzias, Karl Rohrmann, Dolores J Schendel, Christine S Falk, Heike Pohla.   

Abstract

Among tumor-infiltrating lymphocytes (TILs) directly isolated from renal cell carcinomas (RCCs), we found substantial numbers of natural killer (NK) cells in most tumor tissues. They could be identified reliably in situ with an antibody directed against the activating receptor (AR) NKp46 that is exclusively expressed by all NK cells. NK-enriched TILs (NK-TILs) showed cytotoxicity against major histocompatibility complex (MHC) class I-negative cell lines. The ability to detect lysis of target cells was dependent on the percentage of NK cells within the TILs, and cytotoxicity was only observed after overnight activation with low-dose interleukin-2 (IL-2). Infiltrating NK cells were found to express various inhibitory receptors (IRs); among these the CD94/NKG2A receptor complex was overrepresented compared to the autologous peripheral blood mononuclear cell (PBMC) population. Other IRs were underrepresented, indicating that NK subpopulations vary in their tumor-infiltrating capacity. IRs expressed by NK-TILs are functional since receptor engagement with MHC class I ligands presented by human leukocyte antigen (HLA)-transfected target cell lines was able to inhibit NK-mediated cytotoxicity. NK-TILs were also able to lyse autologous or allogeneic tumor cell lines in vitro. This activity correlated with low HLA class I surface expression since lysis could be inhibited by interferon (IFN)-gamma-expressing RCC transductants that displayed a higher surface density of HLA class I molecules. Therefore, NK cells infiltrating tumor tissues have an inherent ability to recognize transformed cells, but they require cytokine activation and are sensitive to inhibition by IR ligands. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12918068     DOI: 10.1002/ijc.11321

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  47 in total

Review 1.  Immunotherapy in metastatic renal cell carcinoma.

Authors:  Karl Rohrmann; Michael Staehler; Nikolas Haseke; Alexander Bachmann; Christian G Stief; Michael Siebels
Journal:  World J Urol       Date:  2005-04-02       Impact factor: 4.226

Review 2.  The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance.

Authors:  Francisco Borrego; Madhan Masilamani; Alina I Marusina; Xiaobin Tang; John E Coligan
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

Review 3.  Dendritic cell interactions with NK cells from different tissues.

Authors:  Guido Ferlazzo; Christian Münz
Journal:  J Clin Immunol       Date:  2009-03-12       Impact factor: 8.317

Review 4.  Natural killer cell activation by dendritic cells: balancing inhibitory and activating signals.

Authors:  Rosa Barreira da Silva; Christian Münz
Journal:  Cell Mol Life Sci       Date:  2011-08-23       Impact factor: 9.261

Review 5.  Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells.

Authors:  Bernhard Frankenberger; Sybille Regn; Christiane Geiger; Elfriede Noessner; Christine S Falk; Heike Pohla; Miran Javorovic; Tobias Silberzahn; Susanne Wilde; Alexander Buchner; Michael Siebels; Ralph Oberneder; Gerald Willimsky; Antonio Pezzutto; Thomas Blankenstein; Dolores J Schendel
Journal:  World J Urol       Date:  2005-07-05       Impact factor: 4.226

6.  Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma.

Authors:  Katherine A Murphy; Britnie R James; Yue Guan; Donald S Torry; Andrew Wilber; Thomas S Griffith
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Epigenetic Mechanisms Dictating Eradication of Cancer by Natural Killer Cells.

Authors:  Suresh Bugide; Radoslav Janostiak; Narendra Wajapeyee
Journal:  Trends Cancer       Date:  2018-07-03

8.  Shaping of NK cell responses by the tumor microenvironment.

Authors:  Ana Stojanovic; Margareta P Correia; Adelheid Cerwenka
Journal:  Cancer Microenviron       Date:  2012-12-16

9.  Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.

Authors:  Marieta Toma; Rebekka Wehner; Anja Kloß; Linda Hübner; Georgia Fodelianaki; Kati Erdmann; Susanne Füssel; Stefan Zastrow; Matthias Meinhardt; Barbara Seliger; Dorothee Brech; Elfriede Noessner; Torsten Tonn; Knut Schäkel; Martin Bornhäuser; Michael P Bachmann; Manfred P Wirth; Gustavo Baretton; Marc Schmitz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

Review 10.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.